All relevant data are within the paper.

Introduction {#sec001}
============

Colorectal cancer (CRC), one of the most prevalent malignant tumors, is the third most commonly diagnosed cancer and the fourth cause of cancer deaths worldwide \[[@pone.0178218.ref001]\]. The mortality and morbidity of CRC rapidly grows in the Chinese population. According to the latest Cancer Statistics of China \[[@pone.0178218.ref002]\], CRC is the fifth newly diagnosed cancer among men, and the fourth among women in China. CRC is considered to be a highly heterogeneous and polygenic disease\[[@pone.0178218.ref003], [@pone.0178218.ref004]\]. The tumorigenesis of CRC is still not completely clear and is thought to be a multistep event. Environmental factors and genetic susceptibility in different cohorts are accepted to play important roles in the tumorigenesis of CRC\[[@pone.0178218.ref005]--[@pone.0178218.ref007]\].

Distant metastasis adversely influences the survival of CRC patients \[[@pone.0178218.ref008]\] and significantly affects the treatment strategies of CRC. Inflammation and immune response play critical roles in CRC progression, including tumor metastasis and poor prognosis. The involvement of the immune system in CRC progression CRC is currently a research hotspot \[[@pone.0178218.ref009], [@pone.0178218.ref010]\]. Tumor necrosis factor-α (TNF-α) is an important pleiotropic cytokine produced by macrophages and is actively involved in immune regulations. TNF-α was thought to be associated with various malignant diseases, including cancer \[[@pone.0178218.ref011], [@pone.0178218.ref012]\]. The levels of elevated plasma TNF-α are commonly associated with poor prognosis \[[@pone.0178218.ref007], [@pone.0178218.ref013]\], such as tumor recurrence and positive lymph-node stage \[[@pone.0178218.ref014], [@pone.0178218.ref015]\]. Meanwhile, TNF-α can induce epithelial mesenchymal transformation and subsequently promotes the invasion and metastasis of colorectal cancer \[[@pone.0178218.ref016], [@pone.0178218.ref017]\]. Single nucleotide polymorphisms in TNF-α gene is reportedly associated with the cancer diagnosis, treatment outcome, and survival of cancer patients \[[@pone.0178218.ref018], [@pone.0178218.ref019]\]. For instance, TNF-α -308 polymorphism is significantly associated with the risk of gastric and hepatocellular carcinomas, triple-negative breast cancer, myeloma, and lymphoma \[[@pone.0178218.ref020]--[@pone.0178218.ref024]\], suggesting that TNF-α may be conducive to the early diagnosis of malignancies.

Some studies have focused on the association between TNF-α -308 polymorphism and CRC risk in different ethnicities and geographical regions worldwide \[[@pone.0178218.ref007], [@pone.0178218.ref024], [@pone.0178218.ref025]\]. However, results are inconsistent. Notably, research has been performed on associations between TNF-α -308 polymorphism and clinical features of CRC, especially in highly aggressive CRC with distant metastasis. In the present work, we conducted a case-control study to explore the role of TNF-α -308 polymorphism in CRC susceptibility, as well as the relationship between genotypes and clinicopathological characteristics.

Patients and methods {#sec002}
====================

Ethics statement {#sec003}
----------------

Our study protocol was approved by the Institutional Review Board of Kunming Medical University. All study subjects provided written informed consent to participate in the study. The study conformed to the tenets of the Declaration of Helsinki. All methods applied were carried out in accordance with the approved guidelines.

Study subjects {#sec004}
--------------

This case-control study included 570 patients with constitutive CRC and 570 cancer-free controls. All subjects were from southwestern China. Patients were recruited from January 2010 to December 2015 in the First Affiliated Hospital of Kunming Medical University & Yunnan Tumor Hospital and had been diagnosed with histologically confirmed CRC. We classified the BC subtypes as colon and rectal cancer. Controls were selected based on a physical examination in the same region during the same period as patient recruitment. The selection criteria included no history of cancer and frequency matching to cases by age and gender. At recruitment, demographic information and clinical characteristics of each participant were collected.

Genotyping {#sec005}
----------

DNA was extracted from leukocytes using a Wizard^®^ Genomic DNA Purification Kit (Promega Corporation, FL, USA) according to the manufacturer's instructions. Genotyping of TNF-α -308 polymorphism (rs1800629) was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Primer sequences are available upon request.

Statistical analysis {#sec006}
--------------------

*Χ*^2^ tests was used to examine the deviation in genotype frequencies from Hardy--Weinberg equilibrium (HWE) in controls and was also used to analyze differences in demographic variables and genotype distributions for different clinical features of CRC. The association of TNF-α- 308 polymorphism with CRC incidence was calculated using adjusted odds ratios (AORs) and 95% confidence intervals (CIs) from multivariate logistic regression. The analysis was performed using SPSS 17.0 (SPSSInc., Chicago, IL, USA). *P* value less than 0.05 was considered statistically significant.

Results {#sec007}
=======

Cases and controls {#sec008}
------------------

We had a total of 570 CRC cases, in which 250 were colon cancer, 316 were rectum cancer, and 4 were both with colon and rectal cancer ([Table 1](#pone.0178218.t001){ref-type="table"}). The demographic characteristics of cases and controls are presented in [Table 1](#pone.0178218.t001){ref-type="table"}.

10.1371/journal.pone.0178218.t001

###### Baseline of colorectal cancer patients and control subjects.

![](pone.0178218.t001){#pone.0178218.t001g}

  Characteristics             Control    CRC^a^       *P*^*b*^
  --------------------------- ---------- ------------ ----------
  **Number**                  570        570          
  Age: years (mean±SDc)       58.5±14    59.1±11.6    0.46
  **Gender**                                          
  male (n%)                   320(56%)   325(57%)     
  famale (n%)                 250(44%)   245(43%)     0.765
  **Hypertension: n%**                   137(24%)     
  **Diabetes Mellitus: n%**              77(13.5%)    
  **BMId≥25kg/m2: n%**                   127(22.3%)   
  **Tumor site: n%**                                  
  Colon                                  250(43.9%)   
  Rectum                                 316(55.4%)   
  **Tumor size: n%**                                  
  \<5cm                                  376(66%)     
  ≥5cm                                   121(21.2)    
  **TNMe stage: n%**                                  
  I                                      73(12.8%)    
  II                                     181(31.8%)   
  III                                    156(27.6%)   
  IV                                     137(24%)     

In this case-control study, the distributions of age and gender were consistently investigated among all cases and controls (P = 0.46 and 0.77, respectively). The genotype frequency of TNF-α-308 G and A alleles in the controls and cases concorded with HWE (P = 0.85 and 0.67, respectively). Considering that CRC is a complicated disease, many risk factors (such as age) are associated with the occurrence and progression of CRC \[[@pone.0178218.ref026], [@pone.0178218.ref027]\]. Therefore, we conducted stratified analysis on the data according to age, gender, tumor site, tumor size, tumor node metastasis (TNM) stage, presence of hypertension, diabetes mellitus, and levels of body Therefore, we conducted a stratified analysis on data according to age, gender, tumor site, tumor size, tumor-node-metastasis (TNM) stage, presence of hypertension, diabetes mellitus, and levels of body mass index (BMI) to determine whether the TNF-α-308 G\>A polymorphism was associated with CRC incidence in specific subsets of the study population.

TNF-α -308 G\>A polymorphism and CRC {#sec009}
------------------------------------

The frequency of TNF-α -308 A allele in CRC patients and relevant normal individuals was 0.070 and 0.067, respectively ([Table 2](#pone.0178218.t002){ref-type="table"}). No significant difference in TNF-α -308 A and G alleles was observed between CRC cases and controls.

10.1371/journal.pone.0178218.t002

###### Allele distribution of TNF-α-308 G and A allele in controls and patients with CRC.
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  Allele   Control   Case   OR95%                  P
  -------- --------- ------ ---------------------- -------
  G        1061      1066   1                      
  A        79        72     0.907 (0.652--1.262)   0.613

Considering the few number of TNF-α -308 AA genotype, the dominant genetic model (GG/GA+AA) was used to analyze the genotype distribution of TNF-α -308 polymorphism. In the dominant genetic model, no significant ([Table 3](#pone.0178218.t003){ref-type="table"}) difference between CRC cases and controls was found in TNF-α -308 polymorphism (OR = 0.884; 95% CI: 0.624--1.251; *P* = 0.535). TNF-α -308 polymorphism was not associated with the risk of colon cancer (OR = 0.895; 95% CI: 0.586--1.367; *P* = 0.661) or rectal cancer (OR = 1.386; 95% CI: 0.895--2.147; *P* = 0.165).

10.1371/journal.pone.0178218.t003

###### Genotype distribution of TNF-α -308 G\>A polymorphism in controls and patients with CRC.
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  Category         GG    GA+AA   OR (95% CI)   *P*                          
  ---------------- ----- ------- ------------- ------ --------------------- -------
  **Controls**     493   86.5    77            13.5   1                     
  **ALL CRC**      500   87.7    69            12.1   0.884(0.624--1.251)   0.535
  **Tumor site**                                                            
  Colon            212   84.8    37            14.8   0.895(0.586--1.367)   0.661
  Rectum           284   89.9    32            10.1   1.386(0.895--2.147)   0.165

TNF-α -308 G\>A polymorphism and clinical risk of CRC {#sec010}
-----------------------------------------------------

To understand the association between TNF-α -308 G\>A polymorphism and clinical features of CRC, logistic regression analysis was used to evaluate the correlations between TNF-α-308 G\>A polymorphism and clinical characteristics (gender, age at diagnosis, BMI, tumor stage, tumor size, lymph-node metastasis, distant metastasis, history of polyp, and family history of cancer by CRC tumor-site classification), as shown in [Table 4](#pone.0178218.t004){ref-type="table"}. In all CRC patients, the GA and AA genotypes were associated with higher BMI index (OR = 2.056; 95% CI: 1.197--3.530; *P* = 0.01) and larger tumor size (OR = 1.81; 95% CI: 1.029--3.183; *P* = 0.042). Notably, TNF-α -308 GA and AA genotypes showed strong association with distant tumor metastasis (OR = 2.911; 95% CI: 1.697--4.992; *P* = 0.00017). Furthermore, rectal cancer patients with TNF-α -308 A allele had a very high risk of distant tumor metastasis (OR = 4.481; 95% CI: 2.072--9.693; *P* = 0.00025), as shown in [Table 4](#pone.0178218.t004){ref-type="table"}. After adjusting tumor stage, pathologic status, tumor size, and lymph-node metastasis status, the association became more significant (OR = 5.549; 95% CI: 2.437--12.632; *P* = 0.000045). The association between TNF-α -308 A allele and distant tumor metastasis remained even significant after adjusting all clinical characteristics (OR = 7.099; 95% CI: 2.482--20.301; *P* = 0.000256) in rectal cancer patients. By contrast, no association between TNF-α -308 GA and AA genotypes and distant metastasis was observed in colon-cancer patients (OR = 1.685; 95% CI: 0.592--4.796; *P* = 0.328). TNF-α -308 G\>A was apparently not associated with other clinical features of CRC in our study.

10.1371/journal.pone.0178218.t004

###### Clinicopathological features of CRC patients classified by tumor site and TNF-α -308 polymorphism.

The total number of individuals may not be the same because of censored data.
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  Characteristics                ALL CRC(n = 570)   Colon cancer   Rectal Cancer                                                                                                                 
  ------------------------------ ------------------ -------------- ------------------------- ------------- ----- ---- ------------------------- ----------- ----- ---- ------------------------- -------------
  **Gender**                                                                                                                                                                                     
  famale(n = 245)                213                31                                                     91    21                                         117   13                             
  male(n = 325)                  287                38             0.91(0.548--1.51)         0.795         121   16   0.573 (0.283--1.16)       0.152       167   19   1.024(0.487--2.155)       1
  **Age(years)**                                                                                                                                                                                 
  ≤59(n = 257)                   226                30                                                     93    18                                         131   12                             
  \>59(n = 313)                  274                39             1.045(0.627--1.74)        0.798         119   19   0.825 (0.41--1.66)        0.596       153   20   1.427(0.672--3.029)       0.454
  **BMI(kg/m2)**                                                                                                                                                                                 
  ≤25(n = 443)                   397                45                                                     168   24                                         226   21                             
  \>25(n = 127)                  103                24             **2.056(1.197--3.530)**   **0.01**      44    13   2.068(0.975--4.388)       0.087       58    11   2.041(0.931--4.472)       0.111
  **Tumour stage**                                                                                                                                                                               
  I+II(n = 264)                  226                37                                                     95    22                                         129   15                             
  III+IV(n = 294)                262                30             0.699(0.419--1.169)       0.193         114   14   0.53(0.257--1.093)        0.104       146   16   0.942(0.448--1.982)       1
  **Tumour size(cm)**                                                                                                                                                                            
  ≤5(n = 376)                    334                41                                                     130   17                                         203   24                             
  \>5(n = 121)                   99                 22             **1.81(1.029--3.183)**    **0.042**     55    16   **2.225(1.049--4.719)**   **0.044**   42    6    1.208(0.465--3.138)       0.62
  **Lymph node metastasis**                                                                                                                                                                      
  NO(n = 296)                    258                38                                                     111   22                                         145   16                             
  YES(n = 256)                   227                28             0.837(0.498--1.408)       0.514         97    13   0.676(0.323--1.414)       0.36        128   15   1.062(0.505--2.234)       1
  **Distant metastasis**                                                                                                                                                                         
  NO (n = 458)0                  414                43                                                     170   25                                         242   18                             
  YES(n = 112)1                  86                 26             **2.911(1.697--4.992)**   **0.00017**   42    12   1.943(0.903--4.182)       0.128       42    14   **4.481(2.072--9.693)**   **0.00025**
  **Family history of cancer**                                                                                                                                                                   
  NO(n = 525)                    459                65                                                     194   35                                         262   30                             
  YES(n = 45)                    41                 4              0.689(0.239--1.987)       0.637         18    2    0.616(0.137--2.773)       0.747       22    2    0.794(0.178--3.544)       1
  **Smoking**                                                                                                                                                                                    
  NO(n = 443)                    391                51                                                     168   27                                         220   24                             
  YES(n = 127)                   109                18             1.266(0.71--2.256)        0.441         44    10   1.414(0.637--3.141)       0.392       64    8    1.146(0.491--2.673)       0.824
  **Alcohol**                                                                                                                                                                                    
  N0 (n = 490)                   430                59                                                     188   31                                         238   28                             
  YES(n = 80)                    70                 10             1.041(0.509--2.131)       1             24    6    1.516(0.574--4.007)       0.413       46    4    0.862(0.286--2.603)       1
  **Hypertension**                                                                                                                                                                               
  NO(n = 433)                    381                51                                                     162   29   0.894(0.384--2.08)        1           215   22                             
  YES(n = 137)                   119                18             1.13(0.636--2.009)        0.764         50    8                                          69    10   1.416(0.639--3.137)       0.393
  **Diabetes Mellitus**                                                                                                                                                                          
  NO(n = 493)                    434                58                                                     181   33                                         249   25                             
  YES(n = 77)                    66                 11             1.247(0.623--2.498)       0.573         31    4    0.708(0.234--2.138)       0.797       35    7    1.992(0.802--4.947)       0.165
  **Cokic Polyp**                                                                                                                                                                                
  NO(n = 405)                    360                45                                                     153   27                                         205   18                             
  YES(n = 164)                   140                24             1.371(0.805--2.336)       0.258         59    10   0.96(0.438--2.106)        1           79    14   2.018(0.958--4.252)       0.068

\* The *P* value shown in Table did not make an adjustment by clinical characters.

TNF-α -308 G\>A polymorphism and physicochemical characteristics of CRC {#sec011}
-----------------------------------------------------------------------

TNF-α is an important cytokine related to immune regulation and inflammation. Therefore, the correlation of TNF-α -308 polymorphism with inflammatory, physiological, and biochemical indices was analyzed in CRC patients. The levels of neutrophil, leukocyte, cholesterol, triglyceride, albumin, high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c) were used to access the relation with TNF-α -308 polymorphism in CRCs patients ([Table 5](#pone.0178218.t005){ref-type="table"}). In all CRC patients, GA and AA genotypes were more frequent in patients with neutrophil percentage exceeding 75% than those with lower neutrophil percentage (OR = 4.764; 95% CI: 2.39--9.495; *P* = 0.000012). However, the association between TNF-α -308 G\>A polymorphism and neutrophil percent disappeared in patients with rectal or colon cancer. TNF-α -308 G\>A polymorphism was associated with the number of neutrophils, which may have resulted from inflammation caused by CRC. In addition to neutrophil percentage, other clinical feathers as listed in [Table 5](#pone.0178218.t005){ref-type="table"} were not associated with TNF-α -308 GA and AA genotypes.

10.1371/journal.pone.0178218.t005

###### Physicochemical characteristic of CRC patients classified by tumor site and TNF-α -308 polymorphism.

The total number of individuals may not be the same because of censored data.
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  Characteristics                                                ALL CRC(n = 570)   Colon cancer   Rectal Cancer                                                                                                     
  -------------------------------------------------------------- ------------------ -------------- ------------------------ -------------- ----- ---- --------------------- ------- ----- ---- --------------------- -------
  **Neutrophil (%)**                                                                                                                                                                                                 
  ≤75 (n = 439)                                                  423                16                                                     170   25                                 216   24                         
  \>75 (n = 131)                                                 111                20             **4.764(2.39--9.495)**   **0.000012**   42    12   1.943(0.903--4.182)   0.128   68    8    1.059(0.455--2.466)   0.831
  **Cholesterol (mmol/L)**                                                                                                                                                                                           
  ≤5.17 (n = 413)                                                359                54                                                     144   28                                 213   26                         
  \>5.17 (n = 156)                                               141                15             0.707(0.386--1.294)      0.314          68    9    0.681(0.304--1.522)   0.442   71    6    0.692(0.274--1.75)    0.52
  **Triglyceride (mmol/L)**                                                                                                                                                                                          
  ≤1.7 (n = 410)                                                 360                50                                                     150   27                                 206   23                         
  \>1.7 (n = 159)                                                140                19             0.977(0.556--1.716)      1              62    10   0.896(0.409--1.962)   0.847   78    9    1.033(0.458--2.331)   1
  **Albumin (g/L)**                                                                                                                                                                                                  
  ≥40 (n = 334)                                                  290                44                                                     124   24                                 164   20                         
  \<40 (n = 235)                                                 210                25             0.785(0.466--1.322)      0.434          88    13   0.763(0.369--1.581)   0.587   120   12   0.82(0.386--1.742)    0.707
  **AST**[^a^](#t005fn001){ref-type="table-fn"} **(U/L)**                                                                                                                                                            
  ≤35(n = 506)                                                   443                63                                                     199   35                                 242   28                         
  \>35(n = 63)                                                   57                 6              0.74(0.307--1.787)       0.551          13    2    0.875(0.189--4.045)   1       42    4    0.823(0.275--2.467)   1
  **ALT**[^b^](#t005fn002){ref-type="table-fn"} **(U/L)**                                                                                                                                                            
  ≤40(n = 535)                                                   470                65                                                     203   36                                 265   29                         
  \>40(n = 34)                                                   30                 4              0.964(0.329--2.825)      1              9     1    0.627(0.077--5.097)   1       19    3    1.443(0.403--5.172)   0.477
  **HDL-c**[^c^](#t005fn003){ref-type="table-fn"} **(mmol/L)**                                                                                                                                                       
  ≥1.29(n = 161)                                                 143                18                                                     56    10                                 85    8                          
  \<1.29(n = 408)                                                357                51             1.135(0.641--2.009)      0.674          156   27   0.969(0.441--2.13)    1       199   24   1.281(0.553--2.967)   0.684
  **LDL-c**[^d^](#t005fn004){ref-type="table-fn"} **(mmol/L)**                                                                                                                                                       
  ≥2.7(n = 303)                                                  279                34                                                     125   22                                 151   12                         
  \<2.7(n = 255)                                                 221                35             1.3(0.785--2.151)        0.366          87    15   0.98(0.481--1.995)    1       133   20   1.892(0.891--4.017)   0.097

^a:^ glutamic oxalacetic transaminase;

^b:^ glutamic-pyruvic transaminase;

^c:^ high density lipoprotein cholesterol;

^d:^ low density lipoprotein cholesterol;

\* The P value shown in Table did not make an adjustment by clinical characters.

Discussion {#sec012}
==========

TNF-α, an important inflammatory cytokine, is mainly produced by activated macrophages \[[@pone.0178218.ref028]\]. Recent studies have shown that TNF-α is actively involved in cellular apoptosis \[[@pone.0178218.ref029]--[@pone.0178218.ref031]\] and immune system\[[@pone.0178218.ref032]--[@pone.0178218.ref034]\]. TNF-α is also considered to be a very important connector between inflammation and cancer progression \[[@pone.0178218.ref035], [@pone.0178218.ref036]\]. These results suggested that TNF-α played a vital role in the etiology and progression of cancer. TNF-α -308 G\>A polymorphism located in the promoter region reportedly influences TNF-α production \[[@pone.0178218.ref037]\]. Some studies have investigated the association between TNF-α -308 G\>A polymorphism and CRC risk, but results are inconsistent \[[@pone.0178218.ref007]\]. Moreover, the association between TNF-α -308 G\>A polymorphism and the clinical features of CRC is rarely studied. Therefore, from the point of view of population genetics, the role of TNF-α -308 G\>A polymorphism in colorectal cancer requires further study.

To further understand the association between TNF-α -308 G\>A polymorphism and CRC, 1140 individuals with or without CRC were enrolled in the present study. We found that TNF-α -308 G\>A polymorphism showed no association with CRC risk in Han Chinese residing in Southwestern China, as shown in Tables [2](#pone.0178218.t002){ref-type="table"} and [3](#pone.0178218.t003){ref-type="table"}. This result was generally consistent with meta-analysis results \[[@pone.0178218.ref032]\] indicating that TNF-α -308 G\>A polymorphism does not confer susceptibility to CRC risk in Eastern populations. Notably, in Western populations, TNF-α -308 G\>A polymorphism is thought to be a risk factor for CRC \[[@pone.0178218.ref032]\]. Therefore, our data further supported the notion that the genetic predisposition of TNF-α-308 G\>A polymorphism to CRC was related to the substantial population heterogeneity.

The association between TNF-α -308 G\>A polymorphism and the clinical features of CRC remains unclear. Recently, Li *et al* \[[@pone.0178218.ref024]\] suggested that the TNF-α-308 A allele is a risk factor of distant metastasis in patients with triple-negative breast cancer. This finding indicates that TNF-α -308 G\>A polymorphism may be involved in cancer progression. In the present work, TNF-α -308 A allele was associated with higher BMI index, larger tumor size, and distant metastasis in CRC patients, as shown in [Table 4](#pone.0178218.t004){ref-type="table"}. Our data showed that TNF-α -308 G\>A polymorphism may be involved in cancer progression. Meanwhile, the correlation between TNF-α -308 A polymorphism and distant metastasis remained in rectal cancer patients ([Table 4](#pone.0178218.t004){ref-type="table"}), indicating that TNF-α -308 G\>A polymorphism may be an important risk factor affecting rectal-cancer patients. The potential role of TNF-α 308 A allele in CRC metastasis requires further verification through animal experiments.

TNF-α -308 G\>A polymorphism was associated with the number of neutrophils in all CRC patients ([Table 5](#pone.0178218.t005){ref-type="table"}), indicating that inflammation in CRC patients may be related to TNF-α -308 G\>A polymorphism. However, the association between TNF-α -308 G\>A polymorphism and the number of neutrophils cannot be further detected in CRC subtypes (rectal and colon cancers), as shown in [Table 5](#pone.0178218.t005){ref-type="table"}. The association between TNF-α-308 G\>A polymorphism and neutrophils may be unrelated to neoplasm location (colon or rectum), although further confirmation is necessary.

There are some limitations in this study. First, the sample size is modest in the present study. It could not fully detect the susceptibility of TNF-α -308 G\>A polymorphism in each subtypes of CRC. Second, the results of the present study did not make a replicated study in another cohort of CRC patients. It should be further verified. Finally, the functional study was not performed to determine the role of TNF-α -308 A allele in distant metastasis of CRC subtypes.

Generally, in Han Chinese of southwestern China, TNF-α -308 G\>A polymorphism may not predispose to CRC risk, but it may significantly increase risk of distant metastasis in rectal cancer patients.

Supporting information {#sec013}
======================

###### Genotype and clinical information for CRC patients in the present study.

(ZIP)

###### 

Click here for additional data file.
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